🔗 Share this article

Given that America proceeds with historic revisions to its vaccination recommendations, a particular individual has emerged unexpectedly: Dr. Tracy Beth Høeg, an American of Danish descent sports medicine doctor and epidemiologist who initially gained attention by casting doubt on coronavirus vaccinations in the pandemic and has concentrated on potential deaths after Covid vaccination in her brief position at the FDA.

Proposed Shifts to Pediatric Immunization Schedule

Agency leaders planned to announce sweeping revisions to the childhood immunization program recently, aligning the US with Denmark’s national calendar, it is understood – a substantial departure that would put the US out of alignment with many the global community with insufficient data for benefit. This reveal has been pushed back until the new year.

In place of Vinay Prasad, Tracy Beth Høeg is set to speak at the gathering. She was just designated temporary leader of the FDA’s CDER, the fifth appointee to lead the office this year.

Consolidating Power at the Regulatory Body

This interim role may indicate a strengthened alliance between the drug and biologics centers as Dr. Høeg and Dr. Prasad strengthen their influence at the regulatory agency – and it signals a increased emphasis upon dismantling long-standing vaccines at the FDA.

Høeg has repeatedly called for halting some pediatric vaccine recommendations in the US to become more similar to Denmark, a nation with nationalized medicine and a population approximately the population of the state of Wisconsin.

So far comments, she has persisted in emphasizing on vaccination policy – typically the responsibility of Dr. Prasad, head of the FDA’s CBER – as opposed to pharmaceutical oversight.

Questions Over Expertise

Høeg has little discernible background in pharmaceutical research, oversight or management, which has been standard for previous leaders of the CBER. She has worked at the FDA as a senior adviser to the agency head and CBER since March.

“She doesn’t seem to have the requisite experience” for overseeing the CDER, stated Jonathan Howard. “She’s never run a scientific study. She lacks experience in running a large organization. She is not an expert in pharmaceutical oversight.”

Previous directors of the center would “be deeply familiar with regulatory frameworks and the science of medication creation”, commented Dr. Janet Woodcock. “Objectively, she has not acquired the type of experience that previous people who headed the center have had.”

CDER has an enormous workload at the FDA, she stated.

“Everybody just focuses on the innovative therapies, but the generic program approves a multitude of off-brand pharmaceuticals. There is also a biosimilars program, OTC medication office and more, and all of those need to be looked after,” she said. “The responsibility you neglect, that is the part that I always told people is going to come back to haunt you.”

There is also, a major leadership aspect to the position, which manages more than 5,000 employees. “It’s a huge management job, if you do it right,” the former official concluded.

Agency Reaction and Contentious Programs

When asked about inquiries about Høeg’s qualifications and whether this assignment represents greater collaboration among agency officials on immunizations, a representative responded that the “concerns stem from inaccurate presumptions”.

“Her resume aligns with the responsibilities of her position,” the official stated, pointing to the time Høeg spent counseling the agency head on “medication safety and oversight research, including computational safety modeling and vaccine surveillance”.

As the temporary head, Høeg assumes responsibility for the agency head's new fast-track approval initiative, a disputed one-day therapy clearance system that reportedly concerned her predecessors. “How are these drugs being picked for this voucher program? Who makes the choices?” Howard said. “There’s a lot of confidentiality going on at the agency right now.”

In general, he stated, “the Food and Drug Administration seems to be moving towards more relaxed rules of most medications, except for vaccines.”

Documented Past Work on Immunizations

Concerning immunizations, Høeg has a more documented, if problematic, past, critics observe. She authored a study using non-validated public submissions to assess the incidence of myocarditis following Covid vaccination. She consulted for the state of Florida top health official Joseph Ladapo, who allegedly have altered data to suggest COVID-19 vaccinations are riskier than they are.

Among her “policy goals” for the incoming government encompassed revising rules for novel immunizations and halting “non-essential” immunizations, she remarked following the vote on a podcast. At the FDA, Dr. Høeg has according to sources suggested preventing young men from receiving COVID-19 vaccinations.

“She’s an complete dogmatist who starts off with her beliefs and reverse-engineers to retrofit the data in a very deceptive, untruthful fashion,” Dr. Howard argued.

Gaining Influence and a “Revenge Tour”

Dr. Høeg joined other contrarians, {like|